Doctor’s own diagnosis drives quest for a cancer cure – eNCA
eNCA |
Doctor’s own diagnosis drives quest for a cancer cure
eNCA Doctor’s own diagnosis drives quest for a cancer cure. Technology; Monday 26 March 2018 – 11:26am. Dr. Christian Hinrichs, an investigator at the National Cancer Institute, speaks about his research in immunotherapy for HPV+ cancers, in his lab at the … |
PharmaTimes |
EU clears first allogenic stem cell therapy
PharmaTimes TiGenix and Takeda’s Alofisel has become the first allogeneic stem cell therapy to be approved for use across the European Union. The therapy (previously referred to as Cx601) has been cleared to treat complex perianal fistulas in adult patients with … Stem cell therapy developers unaffected by Cha Biotech debacleKorea Biomedical Review Stem Cell Therapy Market Status and Trend: Top Key Players, Industry Dynamics, And Regional Scope 2022Healthcare Journal |
PharmaTimes |
EU clears first allogenic stem cell therapy
PharmaTimes TiGenix and Takeda’s Alofisel has become the first allogeneic stem cell therapy to be approved for use across the European Union. The therapy (previously referred to as Cx601) has been cleared to treat complex perianal fistulas in adult patients with … Stem cell therapy developers unaffected by Cha Biotech debacleKorea Biomedical Review Stem Cell Therapy Market Status and Trend: Top Key Players, Industry Dynamics, And Regional Scope 2022Healthcare Journal |
PharmaTimes |
EU clears first allogenic stem cell therapy
PharmaTimes TiGenix and Takeda’s Alofisel has become the first allogeneic stem cell therapy to be approved for use across the European Union. The therapy (previously referred to as Cx601) has been cleared to treat complex perianal fistulas in adult patients with … Stem cell therapy developers unaffected by Cha Biotech debacleKorea Biomedical Review Stem Cell Therapy Market Status and Trend: Top Key Players, Industry Dynamics, And Regional Scope 2022Healthcare Journal |
STAT |
Cancer immunotherapy implants get boost by Novartis licensing
STAT ancer immunotherapy 1 — the process of activating a patient’s own immune system to fight a tumor — is a booming field in drug development. But it faces certain hurdles. Fewer than a quarter of cancer patients benefit from leading drugs in the class … |